Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tusamitamab Ravtansine in Advanced NSQ NSCLC (CARMEN-LC06)
NCT05245071Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Jun 2022
- Primary completion
- Mar 2024
- Modality
- Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 2 trial of tusamitamab ravtansine in non-small cell lung cancer (NSCLC), sponsored by Sanofi. Started Jun 2022; status: terminated.
02
Drugs
tusamitamab ravtansine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05245071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05245071.